Cullinan Therapeutics (CGEM) CLO granted stock option on 230,000 shares

Rhea-AI Filing Summary

Cullinan Therapeutics, Inc. reported that Chief Legal Officer Jacquelyn L. Sumer received a grant of a stock option covering 230,000 shares of common stock. This option was reported as an acquisition of a derivative security.

According to the disclosure, the shares underlying the option vest over four years, with one forty-eighth of the shares vesting in equal monthly installments until the fourth anniversary of the grant date. Following this grant, Sumer was reported as directly holding options on 230,000 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SUMER JACQUELYN L

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.44	02/18/2026		A		230,000		(1)	02/18/2036	Common Stock	230,000	$0	230,000	D

Explanation of Responses:

1. The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.

	/s/ Jacquelyn Sumer	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cullinan Therapeutics (CGEM) report for Jacquelyn L. Sumer?

Cullinan Therapeutics reported that Chief Legal Officer Jacquelyn L. Sumer received a stock option grant for 230,000 shares. The Form 4 classifies this as an acquisition of a derivative security, increasing her directly held option position to 230,000 shares.

How many shares are covered by the new stock option for CGEM’s Chief Legal Officer?

The new stock option granted to CGEM’s Chief Legal Officer covers 230,000 shares of Cullinan Therapeutics common stock. This entire amount is reported as directly held following the transaction, according to the Form 4 filing details.

How do the Cullinan Therapeutics (CGEM) stock options granted to Jacquelyn Sumer vest?

The stock options granted to Jacquelyn Sumer vest over four years. One forty-eighth of the underlying shares vests in equal monthly installments until the fourth anniversary of the grant date, creating a gradual, time-based vesting schedule.

Did the Cullinan Therapeutics (CGEM) Form 4 indicate any sale of shares by Jacquelyn Sumer?

The Form 4 does not indicate any sale of shares by Jacquelyn Sumer. It reports only a grant of a stock option, characterized as an acquisition of a derivative security covering 230,000 shares of common stock.

What type of security did Jacquelyn L. Sumer acquire in the CGEM Form 4 filing?

Jacquelyn L. Sumer acquired a derivative security described as a “Stock Option (Right to Buy).” This option relates to 230,000 shares of Cullinan Therapeutics common stock and is reported as directly owned after the transaction.